Loading...
11 nitric oxide COVID-19 controlled studies, 6 RCTs
44% improvement
for early treatment, RR
0.56
[0.36-0.87]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Winchester (DB RCT)
42%
0.58 [0.36-0.94]
no improv.
8/15
23/25
Improvement, RR [CI]
Treatment
Control
Winchester (DB RCT)
51%
0.49 [0.32-0.75]
viral load
40 (n)
40 (n)
Tandon (DB RCT)
68%
0.32 [0.09-1.12]
no improv.
3/64
10/69
Tandon (DB RCT)
67%
0.33 [0.11-0.97]
no improv.
4/64
13/69
Tandon (DB RCT)
42%
0.58 [0.33-1.01]
no improv.
14/64
26/69
Tandon (DB RCT)
22%
0.78 [0.32-1.89]
no improv.
8/105
10/102
Tandon (DB RCT)
18%
0.82 [0.39-1.75]
no improv.
11/105
13/102
Tandon (DB RCT)
9%
0.91 [0.60-1.38]
no improv.
30/105
32/102
Tandon (DB RCT)
20%
0.80 [0.75-0.86]
viral load
64 (n)
69 (n)
Tandon (DB RCT)
14%
0.86 [0.83-0.90]
viral load
105 (n)
102 (n)
Tandon (DB RCT)
26%
0.74 [0.52-1.05]
viral time
64 (n)
69 (n)
Tandon (DB RCT)
6%
0.94 [0.70-1.25]
viral time
105 (n)
102 (n)
Bryan (DB RCT)
-1%
1.01 [0.21-4.95]
progression
3/261
3/263
Bryan (DB RCT)
11%
0.89 [0.71-1.11]
recov. time
261 (n)
263 (n)
Chandel
-54%
1.54 [0.72-2.78]
death
12/66
36/206
Chandel
-27%
1.27 [0.82-1.73]
ventilation
29/66
79/206
Moni (RCT)
90%
0.10 [0.01-0.76]
death
0/14
4/11
ICU patients
Moni (RCT)
90%
0.10 [0.01-0.76]
ventilation
0/14
4/11
ICU patients
Moni (RCT)
42%
0.58 [0.05-1.00]
no improv.
3/14
7/11
ICU patients
Moni (RCT)
64%
0.36 [0.17-0.74]
viral load
14 (n)
11 (n)
ICU patients
Moni (RCT)
63%
0.37 [0.18-0.75]
viral load
14 (n)
11 (n)
ICU patients
Strickland (RCT)
-179%
2.79 [0.12-64.0]
ventilation
1/19
0/15
Strickland (RCT)
21%
0.79 [0.05-11.6]
hosp.
1/19
1/15
Strickland (RCT)
-38%
1.38 [0.50-3.85]
misc.
7/19
4/15
Poonam
14%
0.86 [0.72-1.04]
death
32/41
56/62
Ventilated patients OT​1 ​
Valsecchi
58%
0.42 [0.02-9.86]
death
0/20
1/51
Valsecchi
68%
0.32 [0.08-1.26]
ventilation
2/20
16/51
Valsecchi
39%
0.61 [0.27-1.39]
ICU
5/20
21/51
Al Sulaiman (ICU)
-40%
1.40 [0.94-2.11]
death
44/56
52/125
ICU patients
Al Sulaiman (ICU)
-18%
1.18 [0.77-1.82]
death
41/56
44/122
ICU patients
Di Fenza (SB RCT)
23%
0.77 [0.44-1.32]
death
94 (n)
99 (n)
Ventilated patients
Di Fenza (SB RCT)
26%
0.74 [0.39-1.40]
death
94 (n)
99 (n)
Ventilated patients
Di Fenza (SB RCT)
13%
0.87 [0.52-1.43]
death
94 (n)
99 (n)
Ventilated patients
Di Fenza (SB RCT)
15%
0.85 [0.50-1.46]
death
94 (n)
99 (n)
Ventilated patients
Di Fenza (SB RCT)
30%
0.70 [0.14-3.39]
progression
94 (n)
99 (n)
Ventilated patients
Di Fenza (SB RCT)
83%
0.17 [0.04-0.62]
misc.
94 (n)
99 (n)
Ventilated patients
SaNOtize
75%
0.25 [0.14-0.43]
cases
13/203
108/422
Nitric oxide COVID-19 outcomes
c19 early .org
April 2024
​1 ​ OT: comparison with other treatment
Favors nitric oxide
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit